Differences in maximum tolerated doses and approval doses of molecularly targeted oncology drug between Japan and Western countries
Author:
Publisher
Springer Science and Business Media LLC
Subject
Pharmacology (medical),Pharmacology,Oncology
Link
http://link.springer.com/content/pdf/10.1007/s10637-014-0080-y.pdf
Reference22 articles.
1. Malinowski HJ, Westelinck A, Sato J, Ong T (2008) Same drug, different dosing: differences in dosing for drugs approved in the United States, Europe, and Japan. J Clin Pharmacol 48:900–908
2. Fukunaga S, Kusama M, Arnold FL, Ono S (2011) Ethnic differences in pharmacokinetics in new drug applications and approved doses in Japan. J Clin Pharmacol 51:1237–1240
3. Arnold FL, Kusama M, Ono S (2010) Exploring differences in drug doses between Japan and Western countries. Clin Pharmacol Ther 87(6):714–720
4. Nakashima K, Narukawa M, Takeuchi M (2011) Approaches to Japanese dose evaluation in global drug development: factors that generate different dosage between Japan and the United States. Clin Pharmacol Ther 90(6):836–843
5. Hyodo I, Shirao K, Doi T, Hatake K, Arai Y, Yamaguchi K et al (2006) A phase II study of the global dose and schedule of capecitabine in Japanese patients with metastatic colorectal cancer. Jpn J Clin Oncol 36(7):410–417
Cited by 18 articles. 订阅此论文施引文献 订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献
1. Dose selection of novel anticancer drugs: exposing the gap between selected and required doses;The Lancet Oncology;2024-08
2. Assessment of Surrogate End Point Trends in Clinical Trials to Approve Oncology Drugs From 2001 to 2020 in Japan;JAMA Network Open;2023-04-28
3. Trends of Phase I Clinical Trials of New Drugs in Mainland China Over the Past 10 Years (2011–2020);Frontiers in Medicine;2021-12-17
4. Surveys/Research Exploring Japanese Phase I Studies in Global Drug Development: Are They Necessary Prior to Joining Global Clinical Trials?;Clinical Pharmacology in Drug Development;2021-11-26
5. Estimating Similarity of Dose–Response Relationships in Phase I Clinical Trials—Case Study in Bridging Data Package;International Journal of Environmental Research and Public Health;2021-02-09
1.学者识别学者识别
2.学术分析学术分析
3.人才评估人才评估
"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370
www.globalauthorid.com
TOP
Copyright © 2019-2024 北京同舟云网络信息技术有限公司 京公网安备11010802033243号 京ICP备18003416号-3